



**MEDICAID / CHIP**  
**PHARMACY PRIOR AUTHORIZATION REQUEST FORM**

Nurtec

Phone: 866-841-7659

Fax back to: 866-240-3712

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.**

Member Name:		Prescriber Name:	
Member ID Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Member Phone Number:	NPI:	PA PROMISe ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:		
Line of Business: <input type="checkbox"/> Medicaid <input type="checkbox"/> CHIP	Specialty Pharmacy (if applicable):		
Drug Name:	Strength:		
Quantity:	Refills:		
Directions:			
Diagnosis Code:	Diagnosis:		
<i>Jefferson Health Plans' maximum approval time is 12 months but may be less depending on the criteria..</i>			

**Please attach any pertinent medical history including labs and information for this member that may support approval.**

***Please answer the following questions and sign.***

Q1. Is the patient prescribed a dose and frequency that is consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature?

Yes

No

Q2. Does the patient have a history of contraindication to the prescribed medication?

Yes

No

Q3. Is this a request for renewal of Nurtec for acute treatment of migraine?

Yes

No

Q4. Is this a request for renewal of Nurtec for preventive treatment of migraine?

Yes

No

Q5. Is the requested drug being prescribed for the treatment of a diagnosis that is indicated in the Food and Drug Administration (FDA)-approved package labeling or a medically accepted indication?

Yes

No

**Nurtec**

**Phone: 866-841-7659**

**Fax back to: 866-240-3712**

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.**

Member Name:	Prescriber Name:
--------------	------------------

Q6. Is the requested drug age-appropriate for the patient according to FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature?

Yes  No

Q7. Is the requested medication being used for the acute treatment of migraine or for the preventive treatment of migraine?

Yes  No

Q8. For the acute treatment of migraine, does the patient have a diagnosis confirmed according to the current International Headache Society Classification of Headache Disorders?

Yes  No

Q9. For the acute treatment of migraine, does the patient have BOTH of the following: a. ONE of the following:  
i. A history of therapeutic failure of at least two (5-HT 1B/1D) receptor agonists (triptans) OR ii. Has a contraindication or intolerance to the preferred triptans b. If currently using a different gepant, ONE of the following: i. Will discontinue use of that gepant prior to starting the requested gepant, ii. Has a medical reason for concomitant use of both gepants that is supported by peer-reviewed literature or national treatment guidelines.

Yes  No

Q10. For acute treatment of migraine, does the quantity exceeds the quantity limit in place?

Yes  No

Q11. For a quantity exceeding the quantity limit in place, does the request meet ALL of the following: a. All criteria guidelines are met, b. The drug is being prescribed by a neurologist or headache specialist who is certified in headache medicine by the UCNS, c. ONE of the following: i. The beneficiary is using the requested medication in addition to at least one medication for migraine prevention (e.g., beta-blocker, anticonvulsant, antidepressant, CGRP monoclonal antibody), ii. The beneficiary has a history of therapeutic failure, contraindication, or intolerance to all preventive migraine medications recommended by current consensus guidelines (such as guidelines from the American Academy of Neurology, American Academy of Family Physicians, American Headache Society) d. The patient was evaluated for the overuse of abortive medications, including opioids.

**Nurtec**

**Phone: 866-841-7659**

**Fax back to: 866-240-3712**

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.**

Member Name:	Prescriber Name:
<input type="checkbox"/> Yes <span style="margin-left: 200px;"><input type="checkbox"/> No</span>	
<p>Q12. For preventive treatment of migraine, is the medication being prescribed by or in consultation with one of the following: a. A neurologist, b. A headache specialist who is certified in headache medicine by the United Council for Neurologic Subspecialties (UCNS).</p> <input type="checkbox"/> Yes <span style="margin-left: 200px;"><input type="checkbox"/> No</span>	
<p>Q13. Is documentation attached showing baseline average number of migraine days and headache days per month?</p> <input type="checkbox"/> Yes <span style="margin-left: 200px;"><input type="checkbox"/> No</span>	
<p>Q14. Has the patient averaged four or more migraine days per month over the previous three months?</p> <input type="checkbox"/> Yes <span style="margin-left: 200px;"><input type="checkbox"/> No</span>	
<p>Q15. Does the patient have a diagnosis of migraine with or without aura confirmed according to the current International Headache Society Classification of Headache Disorders?</p> <input type="checkbox"/> Yes <span style="margin-left: 200px;"><input type="checkbox"/> No</span>	
<p>Q16. Does the patient have a history of therapeutic failure, contraindication, or intolerance of at least one preventive medication from two of the following three classes: a. Beta-blockers (e.g., metoprolol, propranolol, timolol), b. Antidepressants (e.g., amitriptyline, venlafaxine), c. Anticonvulsants (e.g., topiramate, valproic acid, divalproex)</p> <input type="checkbox"/> Yes <span style="margin-left: 200px;"><input type="checkbox"/> No</span>	
<p>Q17. Is the patient currently using a different gepant?</p> <input type="checkbox"/> Yes <span style="margin-left: 200px;"><input type="checkbox"/> No</span>	
<p>Q18. Does the patient meet ONE of the following: a. Will discontinue use of that gepant prior to starting the requested gepant, b. Has a medical reason for concomitant use of both gepants that is supported by peer-reviewed literature or national treatment guidelines.</p> <input type="checkbox"/> Yes <span style="margin-left: 200px;"><input type="checkbox"/> No</span>	

**Nurtec**

**Phone: 866-841-7659**

**Fax back to: 866-240-3712**

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.**

Member Name:	Prescriber Name:
--------------	------------------

Q19. Does the patient have a documented history of therapeutic failure, contraindication, or intolerance to the preferred CGRP monoclonal antibodies (mAbs) approved or medically accepted for the beneficiary's indication?

Yes

No

Q20. For acute treatment of migraine, is documentation attached showing improvement in headache pain, symptoms, or duration?

Yes

No

Q21. For acute treatment of migraine, does the quantity exceeds the quantity limit in place?

Yes

No

Q22. For a quantity exceeding the quantity limit in place, does the request meet ALL of the following: a. All criteria guidelines are met, b. The drug is being prescribed by a neurologist or headache specialist who is certified in headache medicine by the UCNS, c. ONE of the following: i. The beneficiary is using the requested medication in addition to at least one medication for migraine prevention (e.g., beta-blocker, anticonvulsant, antidepressant, CGRP monoclonal antibody), ii. The beneficiary has a history of therapeutic failure, contraindication, or intolerance to all preventive migraine medications recommended by current consensus guidelines (such as guidelines from the American Academy of Neurology, American Academy of Family Physicians, American Headache Society), d. Documentation of an evaluation for the overuse of abortive medications, including opioids.

Yes

No

Q23. For preventive treatment of migraine, is the medication being prescribed by or in consultation with one of the following: a. A neurologist, b. A headache specialist who is certified in headache medicine by the United Council for Neurologic Subspecialties (UCNS).

Yes

No

Q24. Has the patient experienced ONE of the following: a. Has a reduction in the average number of migraine days or headache days per month from baseline, b. Experienced a decrease in severity or duration of migraines from baseline.

Yes

No



**MEDICAID / CHIP**  
**PHARMACY PRIOR AUTHORIZATION REQUEST FORM**

Nurtec

Phone: 866-841-7659

Fax back to: 866-240-3712

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.**

Member Name:	Prescriber Name:
--------------	------------------

Q25. Does the patient have a documented history of therapeutic failure, contraindication, or intolerance to the preferred CGRP monoclonal antibodies (mAbs) approved or medically accepted for the beneficiary's indication?

Yes

No

Q26. Additional Information:

\_\_\_\_\_  
Prescriber Signature

\_\_\_\_\_  
Date

v2026-06